Pivotal phase III trial of ALZ 801 in patients with Alzheimer's disease positive for e4 allele of the apolipoprotein E

Trial Profile

Pivotal phase III trial of ALZ 801 in patients with Alzheimer's disease positive for e4 allele of the apolipoprotein E

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jul 2018

At a glance

  • Drugs ALZ 801 (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Alzheon
  • Most Recent Events

    • 23 Jul 2018 Data from responder analyses of this trial presented in an Alzheon Media Release.
    • 23 Jul 2018 According to an Alzheon media release, data from patient responder analyses of this trial will be presented at 2018 Alzheimers Association International Conference.
    • 02 Nov 2017 According to an Alzheon media release, data will be presented at the 10th Annual Clinical Trials on Alzheimers Disease (CTAD) congress which will be held in 1-4 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top